Jump to content

Draft:Jeong Ho Lee

From Wikipedia, the free encyclopedia
  • Comment: The current draft has to much of what we call puffery, for instance statement such as "His pioneering studies", "He was the first to identify", and "he was honored" as three examples. Please edit, removing anything which appears a little boasting and resubmit. A simpler, dryer version will probably pass. Ldm1954 (talk) 16:11, 30 December 2023 (UTC)
  • Comment: Can you write the award section in prose format rather than listing the awards. Ibjaja055 (talk) 20:15, 29 December 2023 (UTC)

Jeong Ho Lee (이정호, 李柾昊, 1977~) is a physician-scientist in the Republic of Korea. He is a professor at the Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST) as well as a co-founder and Chief Scientific Officer (CSO) at Sovargen..[1] He is best known for his work on brain somatic mutations (or mosaicism) arising from neural stem cells and leading to intractable focal epilepsy and brain tumors. His pioneering studies have laid the groundwork for the biology of brain somatic mutations (or mosaicisms) contributing to various neurological disorders.

Education[edit]

JeongHo Lee studied Medicine in Yonsei University, Korea from 1997 to 2003 and proceeded to finish his doctorate degree in Neuropharmacology at Yonsei University College of Medicine, Korea in 2009.[citation needed]

Career[edit]

Jeong Ho Lee completed his postdoctoral fellowship at the UC San Diego and the Howard Hughes Medical Institute in 2012 with Joseph G. Gleeson. He returned to Korea in 2012 and started working at Korea Advanced Institute of Science and Technology (KAIST) as an Ewon assistant professor. In 2017, He became an associate professor, and then a KAIST endowed chair professor in 2020 and a full professor in 2023. He was elected as a member of Young Korea Academy of Science and Technology (Y-KAST) in 2017.[2] He served as a committee member of FCD Classification Task Force of the Commission on Diagnostic Methods, International League Against Epilepsy (ILAE) (2017-2022).[3] He is a member of ILEA and European Reference Network EpiCare Working Group for diagnosing low-grade and epilepsy associated brain tumor (2023-present).[4]

In 2018, He co-founded Sovargen, a biotech company that develops new diagnostics and therapeutics for neurological disorders with brain somatic mutations. Currently, he is a Chief Scientific Officer (CSO) at Sovargen.[5]

Biography[edit]

He was born on October 18, 1977 in Gwangju, Republic of Korea. He completed his MD (2003) and PhD (2009) at Yonsei University College of Medicine, identifying a new regulatory mechanism of metabotrophic glutamate receptor mGluR5 in neurons in his doctoral program. During his postdoctoral fellowship (2009-2012) at UC San Diego and HHMI, he identified the genes responsible for several developmental brain disorders including Jourbert syndrome and hemimegalencephaly. Then, he joined KAIST at 2012 as a faculty and he has proposed and validated a novel concept of brain-only acquired mutations (referred to as ‘brain somatic mutations or mosaicism’)[6] as a new entity of genetic causes for various incurable human brain disorders. His lab has shown that somatic mutations in a focal brain region actually contribute to several incurable brain disorders with previously unknown etiology, such as focal cortical dysplasia with intractable epilepsy, glioblastoma, pediatric low-grade glioma, schizophrenia, and Alzheimer’s disease.

To translate his research findings to patients, he co-founded Sovargen in 2018, which is a biotech company and develop new RNA therapeutics and diagnostics for brain disorders with somatic mutations. Currently, he is a CSO at Sovargen. Based on his pioneering work, he has been recognized by numerous awards including Innovators in Science Award (shared with Dr. Adrian R. Krainer), New York Academy of Sciences & Takeda in 2020, Kyung Am Award, Kyung-Am Foundation in 2020, and KAISTian of the year in 2018. He was the first to identify the causes of intractable epilepsies and has identified the genes responsible for several developmental brain disorders.[7]

Awards[edit]

In 2009, Jeong Ho Lee received both the Research Award for Basic Medical Science from the Korean Medical Association and the Academic Award for Highest Achievement from the Department of Medical Science at the Graduate School of Yonsei University. By 2010, he was honored with the Trainee Research Semifinalist Award by the American Society for Human Genetics and the Daland Fellowship in Clinical Investigation by the American Philosophical Society[8]. The subsequent years saw his accomplishments grow, with 2013 marking his recognition with the Asan Medical Award as a Young Scientist from the Asan Foundation[9]. In 2015, he was awarded with the Pediatric Epilepsies Award from CURE (Citizens United for Research on Epilepsy) in the USA[10]. Moving forward, 2016 was a notable year for him as he earned the Wunsch Medical Award for Young Medical Scientists from the Korean Medical Association and Boehringer Ingelheim[11], and was also acknowledged in KAIST’s Top 10 Research Accomplishments of 2015[12]. By 2017, he had achieved the Suh Kyungbae Foundation (SUHF) Investigator Award[13] and had become a member of the Young Korean Academy of Science and Technology (Y-KAST)[14]. His accomplishments continued in 2018 when he was recognized as the KAISTian of the Year by KAIST[15]. His most recent recognitions in 2020 include the Early-Career Scientist Award of the 2020 Innovators in Science Award in Rare Diseases by The New York Academy of Sciences[16] and the 15th Kyung-Ahm Prize from the KyungAhm Education & Culture Foundation[17]

Publications[edit]

  1. Calmodulin dynamically regulates the trafficking of the metabotropic glutamate receptor mGluR5[18]
  2. Evolutionarily assembled cis-regulatory module at a human ciliopathy locus[19]
  3. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly[20]
  4. Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy[21]
  5. Human glioblastoma arises from subventricular zone cells with low-level driver mutations[22]
  6. BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors[23]
  7. Low-level brain somatic mutations are implicated in schizophrenia[24]
  8. Brain somatic mutations observed in Alzheimer’s disease associated with aging and dysregulation of tau phosphorylation[25]
  9. Brain somatic mutations as RNA therapeutic targets in neurological disorders[26]

References[edit]

  1. ^ "Professor | Translational Neurogenetics Lab". Retrieved 2023-12-29.
  2. ^ "News at KAIST". www.kaist.ac.kr. Retrieved 2023-12-29.
  3. ^ "International League Against Epilepsy Committee, Commission, Council & Task Force Members" (PDF). International League Against Epilepsy. 2022-09-14. Retrieved 2023-12-28.
  4. ^ "Detection of Brain Somatic Mutations in Cerebrospinal Fluid from Refractory Epilepsy Patients // International League Against Epilepsy". www.ilae.org. Retrieved 2023-12-29.
  5. ^ "Sovargen". Sovargen. Retrieved 2023-12-29.
  6. ^ Kim, Jang Keun; Cho, Jun; Kim, Se Hoon; Kang, Hoon-Chul; Kim, Dong-Seok; Kim, V. Narry; Lee, Jeong Ho (2019-10-01). "Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy". The Journal of Clinical Investigation. 129 (10): 4207–4223. doi:10.1172/JCI127032. ISSN 1558-8238. PMC 6763223. PMID 31483294.
  7. ^ "News at KAIST". www.kaist.ac.kr. Retrieved 2023-12-29.
  8. ^ "Gene Mutations Cause Massive Brain Asymmetry". today.ucsd.edu. Retrieved 2023-12-29.
  9. ^ "아산의학상 수상 이정호·김성한 교수". 데일리메디 (in Korean). Retrieved 2023-12-29.
  10. ^ "Jeong Ho Lee of KAIST receives the 2015 Pediatric Epilepsies Research Award". EurekAlert!. Retrieved 2023-12-29.
  11. ^ "대한의학회. Korean Academy of Medical Sciences". www.kams.or.kr. Retrieved 2023-12-29.
  12. ^ 의과학대학원, 카이스트. "카이스트 의과학대학원". 카이스트 의과학대학원 (in Korean). Retrieved 2023-12-29.
  13. ^ "News at KAIST". www.kaist.ac.kr. Retrieved 2023-12-29.
  14. ^ "News at KAIST". www.kaist.ac.kr. Retrieved 2023-12-29.
  15. ^ 의과학대학원, 카이스트. "카이스트 의과학대학원". 카이스트 의과학대학원 (in Korean). Retrieved 2023-12-29.
  16. ^ "News at KAIST". www.kaist.ac.kr. Retrieved 2023-12-29.
  17. ^ 조정호 (2020-09-21). "제16회 경암상 수상자 성낙인·윤주영·이정호·황철성 교수". 연합뉴스 (in Korean). Retrieved 2023-12-29.
  18. ^ Lee, Jeong Ho; Lee, Jinu; Choi, Kyu Yeong; Hepp, Regine; Lee, Jae-Youn; Lim, Mi Kyung; Chatani-Hinze, Mayumi; Roche, Paul A.; Kim, Dong Goo; Ahn, Young Soo; Kim, Chul Hoon; Roche, Katherine W. (2008-08-26). "Calmodulin dynamically regulates the trafficking of the metabotropic glutamate receptor mGluR5". Proceedings of the National Academy of Sciences. 105 (34): 12575–12580. Bibcode:2008PNAS..10512575L. doi:10.1073/pnas.0712033105. ISSN 0027-8424. PMC 2527953. PMID 18715999.
  19. ^ Lee, Jeong Ho; Silhavy, Jennifer L.; Lee, Ji Eun; Al-Gazali, Lihadh; Thomas, Sophie; Davis, Erica E.; Bielas, Stephanie L.; Hill, Kiley J.; Iannicelli, Miriam; Brancati, Francesco; Gabriel, Stacey B.; Russ, Carsten; Logan, Clare V.; Sharif, Saghira Malik; Bennett, Christopher P. (2012-02-24). "Evolutionarily assembled cis-regulatory module at a human ciliopathy locus". Science. 335 (6071): 966–969. Bibcode:2012Sci...335..966L. doi:10.1126/science.1213506. ISSN 1095-9203. PMC 3671610. PMID 22282472.
  20. ^ Lee, Jeong Ho; Huynh, My; Silhavy, Jennifer L.; Kim, Sangwoo; Dixon-Salazar, Tracy; Heiberg, Andrew; Scott, Eric; Bafna, Vineet; Hill, Kiley J.; Collazo, Adrienne; Funari, Vincent; Russ, Carsten; Gabriel, Stacey B.; Mathern, Gary W.; Gleeson, Joseph G. (2012-06-24). "De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly". Nature Genetics. 44 (8): 941–945. doi:10.1038/ng.2329. ISSN 1546-1718. PMC 4417942. PMID 22729223.
  21. ^ Lim, Jae Seok; Kim, Woo-il; Kang, Hoon-Chul; Kim, Se Hoon; Park, Ah Hyung; Park, Eun Kyung; Cho, Young-Wook; Kim, Sangwoo; Kim, Ho Min; Kim, Jeong A.; Kim, Junho; Rhee, Hwanseok; Kang, Seok-Gu; Kim, Heung Dong; Kim, Daesoo (2015). "Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy". Nature Medicine. 21 (4): 395–400. doi:10.1038/nm.3824. ISSN 1546-170X. PMID 25799227. S2CID 9919578.
  22. ^ Lee, Joo Ho; Lee, Jeong Eun; Kahng, Jee Ye; Kim, Se Hoon; Park, Jun Sung; Yoon, Seon Jin; Um, Ji-Yong; Kim, Woo Kyeong; Lee, June-Koo; Park, Junseong; Kim, Eui Hyun; Lee, Ji-Hyun; Lee, Joon-Hyuk; Chung, Won-Suk; Ju, Young Seok (2018). "Human glioblastoma arises from subventricular zone cells with low-level driver mutations". Nature. 560 (7717): 243–247. Bibcode:2018Natur.560..243L. doi:10.1038/s41586-018-0389-3. ISSN 1476-4687. S2CID 51893118.
  23. ^ Koh, Hyun Yong; Kim, Se Hoon; Jang, Jaeson; Kim, Hyungguk; Han, Sungwook; Lim, Jae Seok; Son, Geurim; Choi, Junjeong; Park, Byung Ouk; Heo, Won Do; Han, Jinju; Lee, Hyunjoo Jenny; Lee, Daeyoup; Kang, Hoon-Chul; Shong, Minho (2018). "BRAF somatic mutation contributes to intrinsic epileptogenicity in pediatric brain tumors". Nature Medicine. 24 (11): 1662–1668. doi:10.1038/s41591-018-0172-x. ISSN 1546-170X. PMID 30224756. S2CID 52288020.
  24. ^ Kim, Myeong-Heui; Kim, Il Bin; Lee, Junehawk; Cha, Do Hyeon; Park, Sang Min; Kim, Ja Hye; Kim, Ryunhee; Park, Jun Sung; An, Yohan; Kim, Kyungdeok; Kim, Seyeon; Webster, Maree J.; Kim, Sanghyeon; Lee, Jeong Ho (2021-07-01). "Low-Level Brain Somatic Mutations Are Implicated in Schizophrenia". Biological Psychiatry. Genomic and Synaptic Mechanisms of Schizophrenia. 90 (1): 35–46. doi:10.1016/j.biopsych.2021.01.014. ISSN 0006-3223. PMID 33867114. S2CID 231809645.
  25. ^ Park, Jun Sung; Lee, Junehawk; Jung, Eun Sun; Kim, Myeong-Heui; Kim, Il Bin; Son, Hyeonju; Kim, Sangwoo; Kim, Sanghyeon; Park, Young Mok; Mook-Jung, Inhee; Yu, Seok Jong; Lee, Jeong Ho (2019-07-12). "Brain somatic mutations observed in Alzheimer's disease associated with aging and dysregulation of tau phosphorylation". Nature Communications. 10 (1): 3090. Bibcode:2019NatCo..10.3090P. doi:10.1038/s41467-019-11000-7. ISSN 2041-1723. PMC 6626023. PMID 31300647.
  26. ^ Lee, Sungyul; Lee, Jeong Ho (2022). "Brain somatic mutations as RNA therapeutic targets in neurological disorders". Annals of the New York Academy of Sciences. 1514 (1): 11–20. Bibcode:2022NYASA1514...11L. doi:10.1111/nyas.14786. ISSN 1749-6632. PMID 35527236.

External links[edit]

  1. Graduate School of Medical Science and Engineering, KAIST (gsmse.kaist.ac.kr)
  2. Translational Neurogenetics Laboratory (tnl.kaist.ac.kr)
  3. SoVarGen (http://sovargen.com/main?lang=en)
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Jeong_Ho_Lee&oldid=1196549784"